3,4-二氨基-2-甲基吡唑 硫酸盐 | 20055-01-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 中文名称: 3,4-二氨基-2-甲基吡唑 硫酸盐
• 中文别名: 3,4-二氨基-2-甲基吡唑硫酸盐
• 英文名称: 4,5-diamino-1-methylpyrazole sulfate
• 英文别名: 4,5-diamino-1-methylpyrazole sulfuric acid salt；1-Methyl-1H-pyrazole-4,5-diamine sulfate；2-methylpyrazole-3,4-diamine;sulfuric acid
• CAS: 20055-01-0
• 化学式: C₄H₈N₄*H₂O₄S
• 分子量: 210.214
• InChiKey: CIMLJTZGZLWBJY-UHFFFAOYSA-N

物化性质

• 熔点：
  >198.5°C (dec.)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.07
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  153
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  3,4-二氨基-2-甲基吡唑 硫酸盐 、 丙二酸单乙酯 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 ethyl 3-[ (5-amino-1-methyl-1H-pyrazol-4-yl) amino]-3-oxopropanoate
  参考文献：
  名称：

  [EN] CEPHEM COMPOUNDS
  [FR] CEPHEMES

  摘要：

  本发明涉及一种公式的化合物[I]：其中R1是低级烷基或羟基（低级）烷基，R2是氢或氨基保护基团，或者R1和R2连接并形成低级亚烷基；R3是-A-R6，其中A是键，-NHCO-(CH2CO)n-，低级亚烷基，-NH-CO-CO-或类似物质，R6是(a)或(b)其中R7，R8，R9和R10是独立的氨基，胍基，脒基或类似物质；R4是羧基或受保护的羧基；R5是氨基或受保护的氨基，或药用可接受的盐，一种制备公式化合物[I]的方法，以及一种包括与药用可接受载体混合的公式化合物[I]的药物组合物。

  公开号：

  WO2005027909A1
• 作为产物：
  描述：

  1-methyl-4-nitroso-1H-pyrazol-5-amine 在 palladium 10% on activated carbon 硫酸 、 氢气 作用下， 反应 10.0h， 生成 3,4-二氨基-2-甲基吡唑 硫酸盐
  参考文献：
  名称：

  [EN] CEPHEM COMPOUNDS
  [FR] CEPHEMES

  摘要：

  本发明涉及一种公式的化合物[I]：其中R1是低级烷基或羟基（低级）烷基，R2是氢或氨基保护基团，或者R1和R2连接并形成低级亚烷基；R3是-A-R6，其中A是键，-NHCO-(CH2CO)n-，低级亚烷基，-NH-CO-CO-或类似物质，R6是(a)或(b)其中R7，R8，R9和R10是独立的氨基，胍基，脒基或类似物质；R4是羧基或受保护的羧基；R5是氨基或受保护的氨基，或药用可接受的盐，一种制备公式化合物[I]的方法，以及一种包括与药用可接受载体混合的公式化合物[I]的药物组合物。

  公开号：

  WO2005027909A1

文献信息

• [EN] CEPHEM COMPOUNDS<br/>[FR] COMPOSES CEPHEME
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004039814A1

  公开（公告）日：2004-05-13

  The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种具有以下式[I]的化合物：其中R1是较低的烷基、羟基(较低)烷基或卤代(较低)烷基，R2是氢或氨基保护基，或者R1和R2结合在一起形成较低的烷基或较低的烯基；R3是氢或较低的烷基；R4是；R5是羧基或保护羧基；R6是氨基或保护氨基，或其药学上可接受的盐，一种制备上述式[I]化合物的方法，以及包含上述式[I]化合物与药学上可接受的载体混合物的药物组合物。
• Cephem compounds
  申请人：Yamanaka Toshio

  公开号：US20050096306A1

  公开（公告）日：2005-05-05

  The present invention relates to a compound of the formula [I]: wherein R 1 is lower alkyl or hydroxy(lower)alkyl, and R 2 is hydrogen or amino protecting group, or R 1 and R 2 are bonded together and form lower alkylene; R is -A-R 6 wherein A is bond, —NHCO—(CH 2 CO) n —, lower alkylene, —NH—CO—CO— or the like, and R 6 is wherein R 7 , R 8 , R 9 and R 10 are independently amino, guanidino, amidino or the like; R 4 is carboxy or protected carboxy; and R 5 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种式[I]的化合物：其中R1是较低的烷基或羟基（较低）烷基，而R2是氢或氨基保护基，或者R1和R2结合在一起形成较低的烷基；R是-A-R6，其中A是键，—NHCO—（CH2CO）n—，较低的烷基，—NH—CO—CO—或类似物，而R6是其中R7，R8，R9和R10独立地是氨基，鸟氨酸基，酰胺基或类似物；R4是羧基或保护羧基；而R5是氨基或保护氨基，或其药学上可接受的盐，以及制备式[I]的化合物的方法，以及包含式[I]的化合物与药学上可接受的载体混合的药物组合物。
• [EN] CEPHEM COMPOUNDS<br/>[FR] CEPHEMES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005027909A1

  公开（公告）日：2005-03-31

  The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl or hydroxy (lower) alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene ; R3 is -A-R6 wherein A is bond, -NHCO-(CH2CO)n-, lower alkylene, -NH-CO-CO- or the like, and R6 is (a) ou (b) wherein R7, R8, R9 and R10 are independently amino, guanidino, amidino or the like ; R4 is carboxy or protected carboxy; and R5 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种公式的化合物[I]：其中R1是低级烷基或羟基（低级）烷基，R2是氢或氨基保护基团，或者R1和R2连接并形成低级亚烷基；R3是-A-R6，其中A是键，-NHCO-(CH2CO)n-，低级亚烷基，-NH-CO-CO-或类似物质，R6是(a)或(b)其中R7，R8，R9和R10是独立的氨基，胍基，脒基或类似物质；R4是羧基或受保护的羧基；R5是氨基或受保护的氨基，或药用可接受的盐，一种制备公式化合物[I]的方法，以及一种包括与药用可接受载体混合的公式化合物[I]的药物组合物。
• Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
  作者：Kenji Murano、Toshio Yamanaka、Ayako Toda、Hidenori Ohki、Shinya Okuda、Kohji Kawabata、Kazuo Hatano、Shinobu Takeda、Hisashi Akamatsu、Kenji Itoh、Keiji Misumi、Satoshi Inoue、Tatsuya Takagi

  DOI：10.1016/j.bmc.2007.11.074

  日期：2008.3

  AmpC beta-lactamase is one of the leading causes of Pseudomonas aeruginosa (P. aeruginosa) resistance to cephalosporins. FR259647 is a cephalosporin having a novel pyrazolium substituent at the 3-position and exhibits excellent activity (MIC = 1 mu g/mL) against the AmpC beta-lactamase overproducing P. aeruginosa FP1380 strain in comparison with the third-generation cephalosporins FK518 [Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 454; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 455; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 456; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 457] (MIC = 16 mu g/mL) and ceftazidime (CAZ) (MIC = 128 mu g/mL). The stability of FR259647 and FK518 to AmpC beta-lactamase was evaluated using MIC assays against both the P. aeruginosa PAO1 strain and a PAO1 mutant strain overproducing AmpC beta-lactamase as a differential assay, which indicates that the main difference derives from their stability to AmpC beta-lactamase. A structural analysis using computer simulations indicated that the difference in stability may be due to steric hindrance of the 3-position substituents causing differential affinity. This steric hindrance may disturb entry of the cephalosporins into the binding pocket. We predicted the possibility of inhibition of entry as a potential means of enhancing stability by conformational analysis. In order to validate this speculation, novel FR259647 derivatives 4-9 were designed, calculated, synthesized, and evaluated. As a result, we demonstrated that their probability of entry correlated with the MIC ratio of the mutant strain to the parent strain and supports the validity of our model. (C) 2007 Elsevier Ltd. All rights reserved.